Table 3 Standardized incidence ratios for tMDS by age, sex, race, and initial diagnosis year among ≥ 1-year adult first primary NSCLC, melanoma, RCC and MM survivors in 17 SEER registries, 2000–2017.

From: Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States

Characteristic

NSCLC

Cutaneous Melanoma

RCC

MM

n = 222,246

n = 208,154

n = 132,199

n = 49,513

O

SIR

95% CI

O

SIR

95% CI

O

SIR

95% CI

O

SIR

95% CI

Overall

187

2.16*

(1.86, 2.49)

79

0.92

(0.73, 1.14)

65

1.13

(0.87, 1.43)

88

4.06*

(3.26, 5.01)

Age at first primary neoplasm, years

< 60

13

3.24*

(1.73, 5.54)

[29]

0.94

(0.63, 1.35)

8

1.52

(0.66, 3.00)

16

10.99*

(6.28, 17.85)

60–69

59

2.66*

(2.03, 3.43)

24

1.41

(0.90, 2.09)

40

6.91*

(4.93, 9.40)

70–79

98

1.95*

(1.58, 2.37)

45

1.00

(0.73, 1.33)

27

0.90

(0.59, 1.30)

26

2.20*

(1.44, 3.23)

≥ 80

17

1.66

(0.97, 2.66)

5

0.49

(0.16, 1.15)

6

1.12

(0.41, 2.44)

6

2.30

(0.84, 5.00)

Ptrend

0.01

> 0.20

> 0.20

< 0.001

Sex

Male

111

2.11*

(1.74, 2.54)

52

0.81

(0.60, 1.06)

47

1.12

(0.82, 1.49)

60

4.17*

(3.18, 5.37)

Female

76

2.23*

(1.76, 2.79)

27

1.24

(0.82, 1.81)

18

1.14

(0.68, 1.80)

28

3.86*

(2.56, 5.57)

Pheterogeneity

> 0.20

0.10

> 0.20

> 0.20

Race

White/unknown

158

2.08*

(1.76, 2.43)

78

0.91

(0.72, 1.14)

48

0.94

(0.69, 1.25)

72

4.10*

(3.21, 5.17)

Black

14

2.32*

(1.27, 3.89)

[< 5]

1.58

(0.04, 8.82)

12

2.73*

(1.41, 4.76)

[16]

3.90*

(2.23, 6.33)

Other

15

3.29*

(1.84, 5.42)

5

2.12

(0.69, 4.94)

Pheterogeneity

> 0.20

na

0.01

> 0.20

Initial diagnosis year

2000–2005

47

1.64*

(1.20, 2.18)

22

0.80

(0.50, 1.21)

14

0.78

(0.43, 1.31)

23

3.61*

(2.29, 5.42)

2006–2010

64

2.05*

(1.58, 2.62)

26

0.85

(0.55, 1.24)

26

1.20

(0.79, 1.76)

38

4.98*

(3.52, 6.83)

2011–2016

76

2.84*

(2.23, 3.55)

31

1.11

(0.75, 1.57)

25

1.38

(0.89, 2.03)

27

3.53*

(2.32, 5.13)

Ptrend

0.002

0.20

0.12

> 0.20

Chemotherapy

Any chemotherapy

93

1.60#

(1.29, 1.96)

77

0.90

(0.71, 1.12)

64

1.14

(0.88, 1.46)

27

2.98#

(1.96, 4.34)

No/unknown chemotherapy

94

3.30*

(2.67, 4.04)

< 5

3.33

(0.40, 12.03)

< 5

0.55

(0.01, 3.06)

61

4.84*

(3.70, 6.22)

Pheterogeneity

< 0.001

na

na

> 0.20

Radiation

Any radiation

101

1.62*

(1.32, 1.97)

78

0.92

(0.72, 1.14)

64

1.12

(0.87, 1.43)

73

3.96*

(3.10, 4.98)

No/unknown radiation

86

3.53*

(2.83, 4.36)

 < 5

1.02

(0.03, 5.69)

 < 5

1.27

(0.03, 7.05)

15

4.66*

(2.61, 7.69)

Pheterogeneity

< 0.001

na

na

> 0.20

  1. MM multiple myeloma, NSCLC non-small cell lung carcinoma, O observed, RCC renal cell carcinoma, SEER Surveillance, Epidemiology and End Results Program, SIR standardized incidence ratio, tMDS treatment-related myelodysplastic syndrome, 95% CI 95% confidence interval.
  2. *P < 0.05.
  3. P values to test differences in the SIRs were computed using a likelihood ratio test derived from Poisson regression models stratified by age at first primary neoplasm, sex, race, initial diagnosis year, and stage of NSCLC. Categories with < 5 observations were not specified to maintain patient confidentiality. P-values do not include categories with < 5.
Back to article page